The latest update is out from Neurogene ( (NGNE) ).
Neurogene Inc. announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its NGN-401 Phase 1/2 trial for Rett syndrome. The company remains on track to provide regulatory updates on trial plans in 2025 and has received PRIME designation from the European Medicines Agency, indicating potential to address unmet medical needs. With a cash runway extending into the second half of 2027, Neurogene is well-positioned to complete its future registrational trial for NGN-401 and further develop its gene therapy pipeline.
More about Neurogene
Neurogene Inc. is a clinical-stage company focused on developing genetic medicines for rare neurological diseases. The company is committed to advancing treatments that can significantly improve the lives of patients and families affected by these conditions.
YTD Price Performance: -37.96%
Average Trading Volume: 233,148
Technical Sentiment Signal: Buy
Current Market Cap: $297.9M
For detailed information about NGNE stock, go to TipRanks’ Stock Analysis page.